Keystone Bio advances a more complete explanation of Porphyromonas gingivalis toxic virulence factors as major driver of sporadic Alzheimer’s and chronic inflammation

Keystone Bio (KB), a biotechnology company and frontrunner in developing precision biologics to eliminate Porphyromonas gingivalis (Pg), has released a groundbreaking data that shows bacterial toxic proteins from Pg in the mouth are released into the blood and cross the Blood Brain Barrier (BBB) as the major driver of sporadic Alzheimer’s and chronic inflammation.

This new data supports a “Peripheral” model of Pg blood-transported toxic proteins delivered into the blood and brain versus the earlier literature in which human and animal model studies support the “local gingipains” Alzheimer’s Disease brain model. What this means for Alzheimer’s patients and those at early risk is that KB is developing a specific diagnostic and treatment to eliminate Pg and the flow of these toxic proteins to the brain.

This data can now be integrated into a more unifying “Concept” and explanation for the “Infection Hypothesis” for Alzheimer’s Disease (AD) and other Dementia-related disease(s). A larger HagA Domain virulence factor is found in many AD and some aged matched control brain tissues. Its complex role in local and systemic inflammatory diseases is well understood and further demonstrates systemic blood borne delivery for the bacterial source of “gingipains” in the brain.

This ground-breaking data was presented in three posters at the Alzheimer’s Association International Conference 2021:

  • Porphyromonas gingivalis Outer Membrane Vesicles as the major drivers of and source for the toxic insult and iron accumulation/deposition in Alzheimer’s Disease
  • Further Preclinical Development of a Clinically Effective Bio-therapeutic Against Porphyromonas gingivalis
  • A Study on the Distribution of Porphyromonas gingivalis Repeated Epitope in Hemagglutinin/Adhesion and HagA gingipains Domain Antigen and DNA in Alzheimer brains

Keystone Bio alters the course of disease through this ground-breaking science

Keystone Bio is a clinical stage, biopharmaceutical company with novel disease-modifying, precision, anti-bacterial bio-therapeutics to target an important and largely unaddressed bacterial driver of systemic inflammation that significantly contribute to multiple inflammatory diseases such as heart disease and dementia/Alzheimer’s disease along with companion diagnostics to diagnose/identify people at risk and monitor treatment.

Using KB proprietary methods, KB has identified a bacterial toxic protein that is a primary driver of systemic inflammation. This bacterial toxic protein complex, secreted actively in large amounts by the bacteria for its own survival, has off-site systemic pathology in various end organs such as the brain in AD brain tissues. This virulent protein complex is packaged into distinct outer membrane vesicles, breaking down and crossing the BBB, and impacts the brain parenchyma in specific neuro-anatomic locations consistent with AD development. Those same toxic proteins are delivered throughout the body from their source, spreading systemic inflammation up to and including end organ disease. KB has the only Precision Biologic on the planet that has been shown to eliminate them at their source and is developing the only diagnostic that identifies it in blood.

KB is advancing a clinically validated bio-therapeutic treatment (KB-001 Mab) for the elimination of Pg and all of its virulence factors including the outer membrane vesicles and their toxic protein complex.

Keystone Bio is backed by scientists and medical professionals with over 35 years of experience

Dr Daniel Sindelar, DMD, chief executive officer and co-founder of Keystone Bio, has played the key role globally in establishing oral pathogens causality of systemic disease including Alzheimer’s for the last 10 years.

Dr Sindelar is the first dental professional to receive a preceptorship for Heart Attack and Stroke Prevention, the founder and director of Oral Genomics, LLC, and editor-in-chief of the OSH News Network.

Dr Peter Nara is the chief scientific officer of Keystone Bio and is a highly sought-after consultant in the biotechnology community with special scientific interests in novel mechanisms of virulence, pathogenesis, and host adaptation to infectious diseases and cancer, and development of innovative approaches to diagnostic tests, vaccines, and treatment. Dr Nara has served on many scientific advisory committees and task forces, is an author on more than 125 scientific publications and reviews, and is co-founder, president, and CEO of the Board of Biological Mimetics (BMI) for almost 20 years.